
Sangamo Therapeutics (SGMO) Stock Forecast & Price Target
Sangamo Therapeutics (SGMO) Analyst Ratings
Bulls say
Sangamo Therapeutics is positioned positively due to the increased estimated value of its SIFTER/ZFP platform, particularly attributed to the neurology pipeline, which is now valued at $7 per share. The probability of success for the isa-vec program has been significantly raised to 85%, reflecting enhanced regulatory positioning, despite a cautious adjustment of revenues to account for collaboration value retention. Additionally, the company's commitment to sustainability and its focus on demonstrating positive outcomes in functional cures and lower system costs further strengthen its long-term growth outlook.
Bears say
Sangamo Therapeutics Inc. faces significant challenges that contribute to a negative outlook, primarily due to the unpredictability of future revenues and expenses, as well as its current non-revenue-generating status. The company reported a considerable net loss of $23 million, or $0.11 per share, while taking drastic measures such as a 40% workforce reduction and halting key pipeline projects, which raises concerns about its operational viability. Additionally, the potential risks associated with clinical program execution, regulatory approvals, and emerging competitive pressures further exacerbate the uncertainty surrounding Sangamo's financial future.
This aggregate rating is based on analysts' research of Sangamo Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Sangamo Therapeutics (SGMO) Analyst Forecast & Price Prediction
Start investing in Sangamo Therapeutics (SGMO)
Order type
Buy in
Order amount
Est. shares
0 shares